热门资讯> 正文
Vir Biotechnology宣布首席财务官转型
2026-07-24 20:39
- Vir Biotechnology (VIR) on Friday said Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed interim Principal Financial Officer, effective July 23.
- Jason O’Byrne is leaving the company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition.
- Sabatini has served as Senior Vice President and Chief Accounting Officer for Vir Biotechnology since February 2023. He has more than two decades of experience and was previously Head of Finance at Capsida Biotherapeutics. Before that, he was at Amgen Inc. from 2004 to 2021.
- Press release
More on Vir Biotechnology
- Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead
- Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
- Vir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 2028
- Vir Biotechnology GAAP EPS of -$0.85 misses by $0.93
推荐文章
美股前瞻 | 存储重回风口！高盛唱多闪迪，海力士董事长警告“存储荒”；苹果携手阿里开发中国市场专属大模型
一周财经日历 | 小米、阿里、港交所、泡泡玛特及中际旭创！重磅财报接踵而至；恒指公司下周五公布季检结果
财报前瞻 | 资本开支成关键考验！阿里业绩重磅来袭，云业务收入增速料高达45%，传统电商能否扛住压力？
SpaceX股价从高点回落41%，五年后会在哪里？AI成新引擎，风险同样突出！
戴尔股价创新高，创始人身价今年暴增逾千亿美元，跻身全球第五大富豪
全文 | 京东高管解读Q2财报：外卖业务Q2亏损同比减半，集团整体净利润进入确定性盈利拐点
就业与通胀降温缓解美联储加息压力 美国抵押贷款利率六周来首次下降
一图看懂 | Q2营收、净利齐超预期！中芯国际单季收入首次突破30亿美元，净利润同比狂增263%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
